Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT).
Ramasamy
K
K
Lim
Z Y
ZY
Pagliuca
A
A
Grundy
R
R
Devereux
S
S
Ho
A Y L
AY
Mufti
G J
GJ
D000328:Adult; D000368:Aged; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality; D019337:Hematologic Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D008107:Liver Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage*; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014652:Vascular Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide